At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase 1/1b Study to Evaluate the Safety and Activity of TTX-030 (Anti-CD39) in Combination With Pembrolizumab or Budigalimab and/or Chemotherapy in Subjects With Advanced Solid Tumors
In Brief
A Phase 1 clinical trial evaluating TTX-030, budigalimab and mFOLFOX6, TTX-030, budigalimab and docetaxel, and 6 other interventions for Solid Tumor, Adult. Completed, enrolled 185 participants across 32 sites in 2 countries.
Detailed Summary
This is a phase 1/1b study of TTX-030 in combination therapy, an antibody that inhibits CD39 enzymatic activity, leading to accumulation of pro-inflammatory adenosine triphosphate (ATP) and reduction of immunosuppressive adenosine, which may change the tumor microenvironment and promote anti-tumor immune response. This trial will study the safety, tolerability, pharmacokinetics, pharmacodynamics and anti-tumor activity of TTX-030 in combination with immunotherapy and/or standard chemotherapies.
Study Details
Timeline
Interventions
Dose and schedule per protocol
Dose and schedule per protocol
Dose and schedule per protocol
Dose and schedule per protocol
Dose and schedule per protocol
Dose and schedule per protocol
Dose and schedule per protocol
Dose and schedule per protocol